Licensing of Alemtuzumab
Alemtuzumab reduces disease activity in previously untreated patients with …
Alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment. Our work has led to the licensing of Alemtuzumab in the European Union and Mexico as a first line treatment for active relapsing- remitting multiple sclerosis, with second line licences in Canada and Australia. In work not supported by commercial funding we have shown that the principal adverse effect of alemtazumab, secondary autoimmunity, occurs when the immune system reconstitute by homeostatic proliferation of residual lymphocytes.
Discover more about the NIHR Cambridge BRC
Contact us by phone, email or web for more information.
Events Calendar
Listing relevant events and training sessions for researchers and members of the public.